ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO477

Apolipoprotein M Treatment Restores Kidney Function in Mouse Model of Alport Syndrome

Session Information

Category: Genetic Diseases of the Kidneys

  • 1202 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Molina David, Judith T., University of Miami Katz Family Division of Nephrology and Hypertension, Miami, Florida, United States
  • Tolerico, Matthew, University of Miami Katz Family Division of Nephrology and Hypertension, Miami, Florida, United States
  • Kim, Jin Ju, University of Miami Katz Family Division of Nephrology and Hypertension, Miami, Florida, United States
  • Drexler, Yelena, University of Miami Katz Family Division of Nephrology and Hypertension, Miami, Florida, United States
  • Merscher, Sandra M., University of Miami Katz Family Division of Nephrology and Hypertension, Miami, Florida, United States
  • Fornoni, Alessia, University of Miami Katz Family Division of Nephrology and Hypertension, Miami, Florida, United States
Background

Studies suggest that altered Apolipoprotein M ( APOM) expression is associated with dyslipoproteinemia, atherosclerosis and possibly diabetes, obesity, and inflammation. However, little is known about the role of APOM in the kidney. We previously reported decreased glomerular APOM expression in glomerular diseases. ApoM is a protein linking cholesterol and sphingolipid metabolism, which are both important players in the development of glomerular injury in Alport Syndrome (AS) among other glomerular disorders. Here we test the hypothesis that systemic replacement of ApoM in AS protects from the development of kidney failure.

Methods

To study the role of APOM in the kidney, we analyzed renal APOM expression in a mouse model of progressive renal disease associated with Alport Syndrome (Col4a3 KO mice). We found reduced mRNA and protein expression of APOM in the kidneys of Col4a3 KO mice. To investigate if APOM replenishment would improve renal function in this mouse model, we injected Col4a3 KO mice with recombinant human APOM (rh-APOM). Three groups of mice were studied: (1) Col4a3 +/+ (WT) + vehicle, (2) Col4a3 -/- (KO) + vehicle, and (3) Col4a3 -/- (KO) + rh-ApoM. rh-APOM was administered by weekly intraperitoneal injection starting at 4 weeks of age and until sacrifice at 8 weeks of age.

Results

APOM mRNA and protein expression were markedly reduced in glomeruli and podocytes from Col4a3 KO mice compared to WT mice. Treatment of Col4a3 KO mice with rh-APOM normalized renal APOM levels and prevented the development of renal failure (serum BUN and creatinine), proteinuria (urinary albumin/creatinine ratio), and protected from the development of glomerulosclerosis, tubular atrophy and dilation.

Conclusion

Our results suggest that restoring renal APOM levels in an experimental model of AS protect from renal failure and that treatment with rh-APOM may represent a novel therapeutic strategy for the treatment of glomerular diseases.

Funding

  • NIDDK Support